Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol

Detalhes bibliográficos
Autor(a) principal: Freitas, Felipe
Data de Publicação: 2014
Outros Autores: Estato, Vanessa, Lessa, Marcos A., Tibiriça, Eduardo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/10942
Resumo: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Investigação Cardiovascular. Rio de Janeiro, RJ, Brasil.
id CRUZ_6c3d0282e269f7229b03442a95621bb4
oai_identifier_str oai:www.arca.fiocruz.br:icict/10942
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Freitas, FelipeEstato, VanessaLessa, Marcos A.Tibiriça, Eduardo2015-06-22T12:26:39Z2015-06-22T12:26:39Z2014FREITAS, Felipe et al. Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol. Fundamental & Clinical Pharmacology, v.29 , p.31-40, 2015.1472-8206https://www.arca.fiocruz.br/handle/icict/1094210.1111/fcp.12075engWiley Online LibraryCardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranololinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Investigação Cardiovascular. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Investigação Cardiovascular. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Investigação Cardiovascular. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Investigação Cardiovascular. Rio de Janeiro, RJ, Brasil.Cardiac microvascular rarefaction appears to be involved in hyperthyroidisminduced left ventricular hypertrophy and dysfunction. We investigated the effects of losartan, an AT1 receptor antagonist; diltiazem, a calcium channel blocker; and propranolol, a b-adrenergic receptor antagonist, on cardiac function and structural microcirculatory cardiac alterations in an experimental model of L-thyroxininduced hyperthyroidism in rats. Hyperthyroidism (HYPER) was induced by intraperitoneal injections of L-thyroxin for 35 days (600 lg/kg/day; n = 32). The euthyroid group was treated with distilled water (EUT + VEH; n = 8). On the 14th day, the HYPER group was divided into four groups that received an oral treatment for 21 days with saline (HYPER + VEH; n = 8), losartan (10 mg/kg/day; HYPER + LOS, n = 8), diltiazem (10 mg/kg/day; HYPER + DILT, n = 8), or propranolol (10 mg/kg/day; HYPER + PROP, n = 8). An echocardiographic study was performed at baseline, at the beginning and at the end of the pharmacological treatment protocol (35th day). The structural capillary density in the left ventricle (LV) was analyzed using histochemical analysis with fluorescein isothiocyanateconjugated Griffonia simplicifolia lectin. HYPER + VEH (182 5 mmHg; P < 0.001) presented higher systolic blood pressure (SBP) compared with EUT + VEH (132 3 mmHg). HYPER + LOS (144 2 mmHg), HYPER + DILT (147 3 mmHg) and HYPER + PROP (153 4 mmHg) presented lower SBP compared with HYPER + VEH (P < 0.001). Chronic treatment with losartan, diltiazem, and propranolol reversed cardiac structural microvascular rarefaction (HYPER + VEH 0.16 0.01; EUT + VEH 0.35 0.02; HYPER + LOS 0.46 0.03; HYPER + DILT 0.49 0.02; HYPER + PROP 0.58 0.04 (Vv [cap]/Vv[fib]); P < 0.001) and enhanced the LV ejection fraction of hyperthyroid rats (HYPER + VEH 71 3; EUT + VEH 85 2; HYPER + LOS 90 3; HYPER + DILT 85 3; HYPER + PROP 86 2%; P < 0.05). In conclusion, chronic treatment with losartan, diltiazem, and propranolol improved the cardiac microcirculation and function in an experimental model of hyperthyroidism in rats.Capillary densityCardiac hypertrophyCardiac microvascularRarefactionHyperthyroidismCardiomegaliaHipertireodismoAção Capilarinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1914https://www.arca.fiocruz.br/bitstream/icict/10942/1/license.txt7d48279ffeed55da8dfe2f8e81f3b81fMD51ORIGINALfelipe_freitaseta_IOC_2014.pdfapplication/pdf561421https://www.arca.fiocruz.br/bitstream/icict/10942/2/felipe_freitaseta_IOC_2014.pdfb11dc0d457f8279a779dac4a694b63e5MD52TEXTfelipe_freitaseta_IOC_2014.pdf.txtfelipe_freitaseta_IOC_2014.pdf.txtExtracted texttext/plain44255https://www.arca.fiocruz.br/bitstream/icict/10942/3/felipe_freitaseta_IOC_2014.pdf.txtd4ab6d23cfa81c71603d4f8cc802f460MD53icict/109422022-06-24 13:03:05.596oai:www.arca.fiocruz.br:icict/10942TElDRU7Dh0EgREUgRElTVFJJQlVJw4fDg08gTsODTy1FWENMVVNJVkEKCkFvIGNvbmNvcmRhciBlIGFjZWl0YXIgZXN0YSBsaWNlbsOnYSB2b2PDqiAoYXV0b3Igb3UgZGV0ZW50b3IgZG9zIGRpcmVpdG9zIGF1dG9yYWlzKToKCmEpIERlY2xhcmEgcXVlIGNvbmhlY2UgYSBwb2zDrXRpY2EgZGUgY29weXJpZ2h0IGRhIGVkaXRvcmEgZG8gc2V1IGRvY3VtZW50by4KCmIpIERlY2xhcmEgcXVlIGNvbmhlY2UgZSBhY2VpdGEgYXMgRGlyZXRyaXplcyBwYXJhIG8gUmVwb3NpdMOzcmlvIEluc3RpdHVjaW9uYWwgZGEgRnVuZGHDp8OjbyBPc3dhbGRvIENydXogKEZJT0NSVVopLgoKYykgQ29uY2VkZSDDoCBGSU9DUlVaIG8gZGlyZWl0byBuw6NvLWV4Y2x1c2l2byBkZSBhcnF1aXZhciwgcmVwcm9kdXppciwgY29udmVydGVyIChjb21vIGRlZmluaWRvIGEgc2VndWlyKSwgY29tdW5pY2FyCiAKZS9vdSBkaXN0cmlidWlyIG5vIFJlcG9zaXTDs3JpbyBkYSBGSU9DUlVaLCBvIGRvY3VtZW50byBlbnRyZWd1ZSAoaW5jbHVpbmRvIG8gcmVzdW1vL2Fic3RyYWN0KSBlbSBmb3JtYXRvIGRpZ2l0YWwgb3UgCgpwb3IgcXVhbHF1ZXIgb3V0cm8gbWVpby4KCmQpIERlY2xhcmEgcXVlIGF1dG9yaXphIGEgRklPQ1JVWiBhIGFycXVpdmFyIG1haXMgZGUgdW1hIGPDs3BpYSBkZXN0ZSBkb2N1bWVudG8gZSBjb252ZXJ0w6otbG8sIHNlbSBhbHRlcmFyIG8gc2V1IGNvbnRlw7pkbywgCgpwYXJhIHF1YWxxdWVyIGZvcm1hdG8gZGUgYXJxdWl2bywgbWVpbyBvdSBzdXBvcnRlLCBwYXJhIGVmZWl0b3MgZGUgc2VndXJhbsOnYSwgcHJlc2VydmHDp8OjbyAoYmFja3VwKSBlIGFjZXNzby4KCmUpIERlY2xhcmEgcXVlIG8gZG9jdW1lbnRvIHN1Ym1ldGlkbyDDqSBvIHNldSB0cmFiYWxobyBvcmlnaW5hbCwgZSBxdWUgZGV0w6ltIG8gZGlyZWl0byBkZSBjb25jZWRlciBhIHRlcmNlaXJvcyBvcyBkaXJlaXRvcyAKCmNvbnRpZG9zIG5lc3RhIGxpY2Vuw6dhLiBEZWNsYXJhIHRhbWLDqW0gcXVlIGEgZW50cmVnYSBkbyBkb2N1bWVudG8gbsOjbyBpbmZyaW5nZSBvcyBkaXJlaXRvcyBkZSBxdWFscXVlciBvdXRyYSBwZXNzb2Egb3UgZW50aWRhZGUuCgpmKSBEZWNsYXJhIHF1ZSwgbm8gY2FzbyBkbyBkb2N1bWVudG8gc3VibWV0aWRvIGNvbnRlciBtYXRlcmlhbCBkbyBxdWFsIG7Do28gZGV0w6ltIG9zIGRpcmVpdG9zIGRlIGF1dG9yLCBvYnRldmUgYSBhdXRvcml6YcOnw6NvIAoKaXJyZXN0cml0YSBkbyByZXNwZWN0aXZvIGRldGVudG9yIGRlc3NlcyBkaXJlaXRvcywgcGFyYSBjZWRlciBhIEZJT0NSVVogb3MgZGlyZWl0b3MgcmVxdWVyaWRvcyBwb3IgZXN0YSBMaWNlbsOnYSBlIGF1dG9yaXphciBhIAoKdXRpbGl6w6EtbG9zIGxlZ2FsbWVudGUuIERlY2xhcmEgdGFtYsOpbSBxdWUgZXNzZSBtYXRlcmlhbCBjdWpvcyBkaXJlaXRvcyBzw6NvIGRlIHRlcmNlaXJvcyBlc3TDoSBjbGFyYW1lbnRlIGlkZW50aWZpY2FkbyBlIHJlY29uaGVjaWRvIAoKbm8gdGV4dG8gb3UgY29udGXDumRvIGRvIGRvY3VtZW50byBlbnRyZWd1ZS4KCmcpIFNFIE8gRE9DVU1FTlRPIEVOVFJFR1VFIMOJIEJBU0VBRE8gRU0gVFJBQkFMSE8gRklOQU5DSUFETyBPVSBBUE9JQURPIFBPUiBPVVRSQSBJTlNUSVRVScOHw4NPIFFVRSBOw4NPIEEgRklPQ1JVWiwgREVDTEFSQSBRVUUgQ1VNUFJJVSAKClFVQUlTUVVFUiBPQlJJR0HDh8OVRVMgRVhJR0lEQVMgUEVMTyBSRVNQRUNUSVZPIENPTlRSQVRPIE9VIEFDT1JETy4gQSBGSU9DUlVaIGlkZW50aWZpY2Fyw6EgY2xhcmFtZW50ZSBvKHMpIG5vbWUocykgZG8ocykgYXV0b3IoZXMpIGRvcyAKCmRpcmVpdG9zIGRvIGRvY3VtZW50byBlbnRyZWd1ZSBlIG7Do28gZmFyw6EgcXVhbHF1ZXIgYWx0ZXJhw6fDo28sIHBhcmEgYWzDqW0gZG8gcHJldmlzdG8gbmEgYWzDrW5lYSBjKS4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-24T16:03:05Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol
title Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol
spellingShingle Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol
Freitas, Felipe
Capillary density
Cardiac hypertrophy
Cardiac microvascular
Rarefaction
Hyperthyroidism
Cardiomegalia
Hipertireodismo
Ação Capilar
title_short Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol
title_full Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol
title_fullStr Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol
title_full_unstemmed Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol
title_sort Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol
author Freitas, Felipe
author_facet Freitas, Felipe
Estato, Vanessa
Lessa, Marcos A.
Tibiriça, Eduardo
author_role author
author2 Estato, Vanessa
Lessa, Marcos A.
Tibiriça, Eduardo
author2_role author
author
author
dc.contributor.author.fl_str_mv Freitas, Felipe
Estato, Vanessa
Lessa, Marcos A.
Tibiriça, Eduardo
dc.subject.en.pt_BR.fl_str_mv Capillary density
Cardiac hypertrophy
Cardiac microvascular
Rarefaction
Hyperthyroidism
topic Capillary density
Cardiac hypertrophy
Cardiac microvascular
Rarefaction
Hyperthyroidism
Cardiomegalia
Hipertireodismo
Ação Capilar
dc.subject.decs.pt_BR.fl_str_mv Cardiomegalia
Hipertireodismo
Ação Capilar
description Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Investigação Cardiovascular. Rio de Janeiro, RJ, Brasil.
publishDate 2014
dc.date.issued.fl_str_mv 2014
dc.date.accessioned.fl_str_mv 2015-06-22T12:26:39Z
dc.date.available.fl_str_mv 2015-06-22T12:26:39Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv FREITAS, Felipe et al. Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol. Fundamental & Clinical Pharmacology, v.29 , p.31-40, 2015.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/10942
dc.identifier.issn.pt_BR.fl_str_mv 1472-8206
dc.identifier.doi.pt_BR.fl_str_mv 10.1111/fcp.12075
identifier_str_mv FREITAS, Felipe et al. Cardiac microvascular rarefaction in hyperthyroid rats is reversed by losartan, diltiazem, and propranolol. Fundamental & Clinical Pharmacology, v.29 , p.31-40, 2015.
1472-8206
10.1111/fcp.12075
url https://www.arca.fiocruz.br/handle/icict/10942
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Wiley Online Library
publisher.none.fl_str_mv Wiley Online Library
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/10942/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/10942/2/felipe_freitaseta_IOC_2014.pdf
https://www.arca.fiocruz.br/bitstream/icict/10942/3/felipe_freitaseta_IOC_2014.pdf.txt
bitstream.checksum.fl_str_mv 7d48279ffeed55da8dfe2f8e81f3b81f
b11dc0d457f8279a779dac4a694b63e5
d4ab6d23cfa81c71603d4f8cc802f460
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324957007052800

Registros relacionados